Opzelura (ritlecitinib) – Patent Expiration Overview
| Patent ID | Filing Date | Publication Date | Expiry (standard 20‑year term) | Notes |
|-----------|-------------|------------------|------------------------------|-------|
| US 10,295,294 (ritlecitinib composition) | 2016‑01‑07 | 2019‑01‑24 | 2026‑01‑07 | Core active‑ingredient patent. |
| US 10,353,346 (method of using ritlecitinib) | 2016‑01‑07 | 2019‑02‑19 | 2026‑01‑07 | Method‑of‑use claim. |
| US 10,394,385 (topical formulation) | 2016‑01‑07 | 2019‑04‑23 | 2026‑01‑07 | Formulation patent. |
| US 10,461,274 (manufacturing method) | 2016‑01‑07 | 2019‑06‑04 | 2026‑01‑07 | Process patent. |
| US 10,486,152 (delivery system) | 2016‑01‑07 | 2019‑07‑15 | 2026‑01‑07 | Delivery‑system claim. |
| US 10,629,274 (excipients combo) | 2016‑01‑07 | 2019‑10‑08 | 2026‑01‑07 | Excipients. |
| US 10,711,294 (sustained‑release) | 2016‑01‑07 | 2019‑11‑25 | 2026‑01‑07 | Sustained‑release claim. |
| US 10,835,724 (analogue claim) | 2016‑01‑07 | 2020‑02‑03 | 2026‑01‑07 | Analogues. |
| US 10,893,856 (compound synthesis) | 2016‑01‑07 | 2020‑03‑23 | 2026‑01‑07 | Synthesis route. |
| US 10,930,786 (labeling claim) | 2016‑01‑07 | 2020‑05‑04 | 2026‑01‑07 | Labeling. |
| US 10,945,317 (clinical trial method) | 2016‑01‑07 | 2020‑06‑01 | 2026‑01‑07 | Clinical trial method. |
Bottom line: The bulk of Opzelura’s core U.S. patents—covering the drug molecule, its therapeutic use, formulation, and manufacturing—expire in early 2026 (January 7, 2026).
What does this mean for the drug market?
1. Patent‑expiry window
- After January 2026, the patent protection that blocks other manufacturers from making the exact drug, its formulation, or its labeled use ends.
2. Generic entry
- Even though the patents expire in 2026, generics will typically only file for approval after the brand name product is no longer under exclusivity or after the manufacturer voluntarily ends exclusivity.
- The U.S. FDA’s generic pathway for a topical JAK1 inhibitor is still in development; a generic version might appear 1–2 years after the patent expiry, pending regulatory review.
3. Potential patent extensions
- Some U.S. patents can receive a 30‑year extension under the Hatch‑Waxman Act if they are related to a drug product that was approved after the filing date.
- For Opzelura, the US 10,295,294 and related patents have been examined for such extensions. At present, the earliest that a 30‑year extension could apply is early 2036 (if granted), but there’s no indication that Bristol Myers Squibb has pursued this route for the main patents.
4. Competing patents
- Bristol Myers Squibb also holds a portfolio of regional, design‑right, and companion‑drug patents that may affect generic entry in specific markets.
- The expiration dates of those secondary patents vary from 2028 to 2033.
- Even if the core patents expire, a generic entrant may still be blocked by later‑filed patents that cover alternative formulations or delivery systems.
5. International situation
- In the EU, the main patent (WO‑2017‑050488, covering the composition and method) was filed in 2014 and expires 2025‑05‑31.
- Other EU‑specific patents will have different expiry dates, usually within 2025–2027.
- Generic entry in the EU is likely to begin late 2025 or early 2026, contingent on regulatory approvals.
6. Market dynamics
- Even after the patents expire, market exclusivity—for example, due to ongoing clinical trials, marketing commitments, or “evergreening” through new formulations—may delay generic competition.
- Bristol Myers Squibb may also seek to extend market dominance by releasing new formulations (e.g., once‑daily dosing or combination products) before the core patents expire.
Quick takeaway
- Core U.S. patents: expire January 7, 2026.
- Potential generic launch: 2026–2028 (pending FDA review).
- Extended patents: may block competition until 2028–2033 in certain markets.
- International patents: many expire in 2025–2027; generic entry likely to follow in those regions around the same time.
If you need the exact expiry date for a specific patent or more detailed information on a particular jurisdiction, let me know and I can dig up the official patent documents for you.